Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...

Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...

2024 — A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy to all patients straight after diagnosis can drastically improve ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

Studies show how some plant foods can reduce inflammation, prevent flare-ups and even lower surgery risks for those with ...

Crohn’s disease and ulcerative colitis are both inflammatory bowel diseases with similar symptoms. However, some key differences include the areas they affect, diagnostic tools, and treatment plans.

Take Steps is the Crohn’s & Colitis Foundation’s signature fundraising event. This year (2025), the event will take place at Citizen’s Bank Park on May 9th. Funds raised at Take Steps ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for moderately to severely active Crohn’s disease.